H. Lundbeck A/S

CPSE:HLUN A Stock Report

Market Cap: DKK 43.3b

H. Lundbeck Past Earnings Performance

Past criteria checks 3/6

H. Lundbeck has been growing earnings at an average annual rate of 7%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 4.3% per year. H. Lundbeck's return on equity is 11.3%, and it has net margins of 12.5%.

Key information

7.0%

Earnings growth rate

7.0%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate4.3%
Return on equity11.3%
Net Margin12.5%
Next Earnings Update05 Feb 2025

Recent past performance updates

Recent updates

Take Care Before Diving Into The Deep End On H. Lundbeck A/S (CPH:HLUN A)

Jan 07
Take Care Before Diving Into The Deep End On H. Lundbeck A/S (CPH:HLUN A)

H. Lundbeck's (CPH:HLUN A) Soft Earnings Are Actually Better Than They Appear

Nov 17
H. Lundbeck's (CPH:HLUN A) Soft Earnings Are Actually Better Than They Appear

Getting In Cheap On H. Lundbeck A/S (CPH:HLUN A) Is Unlikely

Jul 20
Getting In Cheap On H. Lundbeck A/S (CPH:HLUN A) Is Unlikely

Revenue & Expenses Breakdown

How H. Lundbeck makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CPSE:HLUN A Revenue, expenses and earnings (DKK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2421,4412,6879,1624,361
30 Jun 2420,6712,5869,1733,654
31 Mar 2420,2392,2989,0413,549
31 Dec 2319,9122,2908,7063,457
30 Sep 2319,6142,4678,3623,381
30 Jun 2319,3812,4798,1153,471
31 Mar 2318,9182,3848,0823,617
31 Dec 2218,2461,9167,6893,754
30 Sep 2217,6191,6037,3983,846
30 Jun 2216,9131,2367,1273,947
31 Mar 2216,3981,1096,7683,884
31 Dec 2116,2991,3186,6253,820
30 Sep 2116,5211,8736,6983,711
30 Jun 2116,9711,9656,6803,655
31 Mar 2117,3812,1106,7202,999
31 Dec 2017,6721,5816,9123,753
30 Sep 2017,8189046,8123,760
30 Jun 2017,4901,2426,7443,538
31 Mar 2017,3661,5076,6724,039
31 Dec 1917,0362,3136,4133,116
30 Sep 1916,8113,0916,2123,214
30 Jun 1917,3093,3956,1433,302
31 Mar 1917,7663,6066,0613,313
31 Dec 1818,1173,9076,0393,277
30 Sep 1818,3133,8066,1203,069
30 Jun 1818,0283,6276,1742,903
31 Mar 1817,6083,2366,2982,765
31 Dec 1717,2342,6246,4822,705
30 Sep 1717,0072,5446,4282,769
30 Jun 1716,6071,9886,4622,839
31 Mar 1716,0751,6126,4242,887
31 Dec 1615,6341,2116,2932,967
30 Sep 1615,2022906,475-1,979
30 Jun 1614,923-1,2897,3203,196
31 Mar 1614,801-5,4277,5733,095
31 Dec 1514,594-5,6947,7623,097
30 Sep 1514,108-5,8797,8148,003
30 Jun 1513,625-4,6156,9282,666
31 Mar 1513,444-5656,5812,790
31 Dec 1413,468-1536,2982,689
30 Sep 1413,8085036,2082,670
30 Jun 1414,1817656,1472,782
31 Mar 1414,2691196,8142,807
31 Dec 1315,2588556,7492,834

Quality Earnings: HLUN A has high quality earnings.

Growing Profit Margin: HLUN A's current net profit margins (12.5%) are lower than last year (12.6%).

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: HLUN A's earnings have grown by 7% per year over the past 5 years.

Accelerating Growth: HLUN A's earnings growth over the past year (8.9%) exceeds its 5-year average (7% per year).

Earnings vs Industry: HLUN A earnings growth over the past year (8.9%) did not outperform the Pharmaceuticals industry 8.9%.

Return on Equity

High ROE: HLUN A's Return on Equity (11.3%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y